摘要
第一部分肿瘤抑制基因RECK在骨肉瘤组织中表达的初步研究
[目的]通过检测RECK基因在人骨肉瘤组织中的表达，探讨RECK基因在骨肉瘤发生及转移过程中的作用。
[方法]采用免疫组化学方法检测38例骨肉瘤组织标本及38例正常骨组织中RECK蛋白的表达水平。
[结果]38例骨肉瘤组织中有26例RECK蛋白呈弱表达或未见表达，而在所38例正常的骨组织标本中RECK均有表达且呈强表达，骨肉瘤组织、正常骨组织中RECK的吸光度值分别为(0．31±0．07)和(0．58±0．08)，骨肉瘤组织RECK的表达明显低于正常骨组织(P＜0．01)，差异具有统计学意义；RECK蛋白表达与患者年龄、性别、肿瘤大小、病理分级等均无密切关系，而RECK的低表达或不表达与肺转移有关(P＜0．05，P=0．019)。
生存资料分析显示，RECK蛋白高表达患者的平均生存时间为31个月，低表达患者的平均生存时间为15个月，经Log-rank检验，RECK高表达患者与低表达患者的累计生存率差异有统计学意义(P＜0．05，P=0．032)。
[结论] RECK基因异常低表达可能参与骨肉瘤侵袭、转移机制，RECK基因可能成为判断骨肉瘤患者预后新的分子标志物及肿瘤治疗的新靶点。
第二部分转染RECK基因对人骨肉瘤细胞MMP-2活化及侵袭能力的影响研究
[目的]观察转染RECK基因对人骨肉瘤胞系MG-63的MMP-2活化及细胞侵袭力的影响。
[方法]以脂质体Lipofectamine~(TM) 2000介导的方法将含RECK全长基因的真核重组表达质粒pcDNA3-RECK转染入MG-63细胞。RT-PCR、Western blot、流式细胞术检测目的基因的表达；明胶酶谱法、Matrigel侵袭实验分别检测MG-63细胞上清的MMP-2活化比例及细胞侵袭力变化；四甲基偶氮唑蓝(MTT)比色法和细胞生长曲线法观察质粒DNA转染对细胞的毒性情况。
[结果]转染后RECK基因在MG-63细胞mRNA和蛋白水平分别有稳定独立表达；明胶酶谱结果显示，正常对照组与空载质粒转染组细胞的MMP-2活化比例分别为(0．72±0．11)，(0．80±0．14)，二组间差异无显著性意义；重组质粒转染组MMP-2活化比例为(0．23±0．03)，与正常对照组、空载质粒转染组比较明显降低，差异有显著性意义(均P＜0．01)。Matrigel侵袭实验结果显示：正常对照组与空载质粒转染组的穿至微孔膜下表面的细胞数分别为(28．18±2．15)和(30．25±2．23)，两组间差异无显著性意义(P＞0．05)。重组质粒转染组穿透Matrigel至微孔膜下表面的细胞数为(14．20±1．26)，明显低于正常对照组、空载质粒转染组，差异有显著性意义(均P＜0．05)。而MTT法测重组质粒转染组细胞生长曲线与空白对照组、空载质粒转染组无明显差异(均P＞0．05)。
[结论] RECK基因过表达可显著减少骨肉瘤细胞MG-63的MMP-2活化及其侵袭能力，RECK基因可能成为肿瘤治疗的新的靶点。
Part one
The preliminary study on the expression of the tumorinhibitory gene RECK in the osteosarcoma tissues
[Objective] To detect the the expression of RECK gene in osteosarcoma tissuesexplore its possible roles on the occurrence and metastasis of osteosarcoma.
[Methods] The expression level of RECK protein in 38 osteosarcoma tissues and 38normal bone tissues were detected by immunohistochemistry.
[Results] Of the 38 osteosarcomas examined,26 were stained weak or negative forRECK,whereas the strong RECK staining was observed in all 38 normal bone tissues.Theabsorbent optical density value of RECK protein in osteosarcoma tissues and normalbone tissuses were (0.31±0.07) and (0.58±0.08),respectively.The expression of RECK inosteosarcoma tissues was significantly lower than that in normal bone tissuse(P＜0.01).RECK protein expression was significant correlated with the pulmonary metastasis(P＜0.05,P=0.019),but had no correlation with age,sex,tumor size and pathologic grades.Ina comparison between the patients with RECK-positive tumors and patients withRECK-negative tumors,the survival time of the RECK-positive group was found to be 31months,whereas that of the RECK-negative group was 15 months,indicating theRECK-positive group had significantly better survival rate than the RECK-negative group(P＜0.05,P=0.032 by Log-rank test).
[Conclusion] The abnoamal low expression of RECK may participate in osteosarcomainvasion and metastasis,and may be a new prognostic molecular marker for osteosarcoma and a new therapeutic target for tumor.
Part two
The study of transfecting RECK gene on MMP-2 activationand invasional ability of human osteosarcoma cell
[Objective] To investigate effect of transfecting RECK gene on MMP-2 activation andinvasional ability of human osteosarcoma cell line MG-63.
[Methods] The recombinant eukaryotic expression vector pcDNA3-RECK inserted bythe full length cDNA encoding human RECK gene was stably transfected into MG-63 byLipofectamine~(TM) 2000.RT-PCR,westem blot and flow cytometric analysis were used toassay RECK gene expression.MMP-2 activation ratio of the cell supematant and cellinvasional ability of MG-63 were analyzed by gelatinase zymography and matrigel invasionassay,respectively.The cytotoxicity of plasmid DNA transfection on MG-63 cells weredetermined by MTT assay and cell growth curve method.
[Results] The stable and higher expression of RECK in mRNA and protein level weredetected in MG-63,respectively.Gelatinase zymography showed MMP-2 activation ratio intransfecting blank plasmid group and normal control group were (0.72±0.11),(0.80±0.14).Nosignificant difference was found between them.However,the MMP-2 activation ratio intransfecting recombinant plasmid group was (0.23±0.03),which was obviously less thanthose in transfecting blank plasmid group and normal control group(both P value＜0.01).Mrtrigel invasion assay showed cell number invading through Matrigel in transfecting blankplasmid group and normal control group were (28.18±2.15)and(30.25±2.23),respectively.Nosignificant difference was found between them.The cell number invading through Matrige intransfecting recombinant plasmid group was (14.20±1.26),which was dramatically decreasedcompared with those in transfecting blank plasmid group and normal control group(both Pvalue＜0.05).MTT showed no significant difference was found in transfecting recombinant plasmid group compared with transfecting blank plasmid group and normal control group incomparing cell growth curve (both P value＞0.05).
[Conclusion] Over expression of RECK gene significantly inhibited MMP-2 activationand cell invasional ability of osteosarcoma cell MG-63,suggesting RECK may be a newtarget for osteosarcoma treatment.
引文
1. Mankin HJ, Hornicek FJ, Rosenberg AE, Harmon DC, Gebhardt MC.Survival data for 648 patients with osteosarcoma treated at one institution[J]. Clin Orthop Relat Res 2004,429:286-291.
2. Wada T, Isu K, Takeda N, Usui M, Ishii S, Yamawaki S. A preliminary report of neoadjuvant chemotherapy NSH-7 study in osteosarcoma:preoperative salvage chemotherapy based on clinical tumor response and the use of granulocyte colony-stimulating factor[J]. Oncology 1996,53(3):221-227.
3. Stewart DA, Cooper CR, Sikes RA.Changes in extracellular matrix (ECM) and ECM-associated proteins in the metastatic progression of prostate cancer[J].Reprod Biol Endocrinol, 2004,2: 2.
4. Matsunaga Y, Koda M, Murawaki Y. Expression of matrix metalloproiteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs) in hepatocellular carcinoma tissue,compared with the surrounding non-tumor tissue[J].Res Commun Mol Pathol Pharmacol, 2004,115-116: 143-150.
5. Massova I, Kotra LP, Fridman R, et al. Matrix metalloproteinases: structures, evolution,and diversification[J]. FASEB J ,1998,12(12):1075-1095.
6. Lee PP, Hwang JJ, Murphy G,et al.Functional significance of MMP-9 in tumor necrosis factor-induced proliferation and branching morphogenesis of mammary epithelial cells[J].Endocrinology,2005,141(10):3764-3773.
7. Bjornland K, Flatmark K, Pettersen S, et al. 2005. Matrix metalloproteinases participate in osteosarcoma invasion[J].J Surg Res, 2005, 127(2): 151-156.
8. Tanimura S, Kadomoto R, Tanaka 7,et al.Suppression of tumor cell invasiveness by hydrolyzable tannins (plant polyphenols) via the inhibition of matrix metalloproteinase-2/-9 activity[J]. Biochem Biophys Res Commun, 2005, 330(4):1306-1313.
9. Ferrari C, Benassi S, Ponticelli F, et al. Role of MMP-9 and its tissue inhibitor TIMP-1 in human osteosarcoma:findings in 42 patients followed for 1-16 years[J]. Acta Orthop Scand.2004,75(4):487-491.
10. Takabashi C, Sheng Z, Horan TP, et al.Regulation of matrixmetalloproteinase-9 and inhibition of tumor invasion by the membrahe-anchored glycoprotein RECK[J]. Proe Nail Acad Sci USA,1998,95(22):13221-13226.
11. Oh J, Takahashi R, Kondo S, et al. The membrane-anchored MMP inhibitor RECK is a key regulator of extracellular matrix integrity and angiogenesis[J]. Cell, 2001,107(6): 789-800.
12. Rhee JS, Coussens LM. RECKing MMP function: implications for cancer Development[J]. Trends in Cell Biology, 2002,12 (5):209-211.
1. Takahashi C, Sheng Z, Horan TP, et al. Regulation of matrix metaloprotease-9 and inhibition of tumour invasion by the membrane-anchored glycoprotein RECK[J]. Proc Natl Acad Sci USA, 1998, 95(10):13221-13226.
2. Rhee JS,Coussens LM.RECKing MMP function:implications for cancer development[J]. Trends Cell Biol, 2002, 12(5):209- 211.
3. Oh J, Takahashi R, Kondo S, et al. The membrane-anchored MMP inhibitor RECK is a key regulator of extracellular matrix integrity and angiogenesis[J]. Cell, 2001, 107(6):789-800.
4. Takeuchi T, Hisanaga M, Nagao M, et al.The Membrane-Anchored Matrix Metalloproteinase (MMP) Regulator RECK in Combination with MMP-9 Serves as an Informative Prognostic Indicator for Colorectal Cancer[J]. Clin. Cancer Res, 2004, 10(16): 5572 - 5579.
5. Choong P. The molecular basis of skeletalmetastases[J].Clin Orthop, 2003, 415S:S19-31.
6. Kansara M, Thomas DM. Molecular pathogenesis of osteosarcoma[J]. DNA Cell Biol, 2007, 26(1): 1-18.
7. Bjornland K, Flatmark K, Pettersen S, et al. Matrix metalloproteinases participate in osteosarcoma invasion[J].J Surg Res, 2005,127(2): 151-156.
8. Yoon SO, Park SJ, Yun CH, et al.Roles of matrie-Anchored MMP Inhibitor RECK Is a key regulator of extracellular matrix integrity and angiogenesis [J] .Cell, 2001,107(6):789-800.
9. Ferrari C, Benassi S, Ponticelli F, et al. Role of MMP-9 and its tissue inhibitor TIMP-1 in human osteosarcoma.-findings in 42 patients followed for 1-16 years[J]. Acta Orthop Scand.2004,75(4):487-491.
10. Takemoto N, Tada M, Hida Y, et al. Low expression of reversion-inducing cysteine-rich protein with Kazal motifs (RECK) indicates a shorter survival after resection in patients with adenocarcinoma of the lung[J]. Lung Cancer, 2007, 58(3): 376-383.
11. Van der jagt MF, Sweep FC, Waas ET,et al. Correlation of reversion-inducing cysteine-rich protein with kazal motifs (RECK) and extracellular matrix metalloproteinase inducer (EMMPRIN), with MMP-2, MMP-9, and survival in colorectal cancer[J]. Cancer Lett, 2006,237(2): 289-297.
12. Clark JC, Thomas DM, Choong PF, et al. RECK-a newly discovered inhibitor of metastasis with prognostic significance in multiple forms of cancer[J]. Cancer Metastasis Rev, 2007, 26(3-4): 675-683.
13. Kang HG, Kim HS, Kim KJ, et al. RECK expression in osteosarcoma: correlation with matrix metalloproteinases activation and tumor invasiveness[J]. J Orthop Res, 2007,25(5): 696-702.
1. Pantel K, Brakenhoff RH. Dissecting the metastatic cascade[J]. Nat Rev Cancer ,2004,4:448-456.
2. Geho DH, Bandle RW, Clair T, et al. Physiological mechanisms of tumor-cell invasion and migration[J]. Physiology (Bethesda) ,2005,20: 194-200.
3. Lynch CC, Matrisian LM. Matrix metalloproteinases in tumorhost cell communication[J]. Differentiation ,2002,70: 561-573.
4. Fingleton B. Matrix metalloproteinases: roles in cancer and metastasis[J].Front Biosci,2006,11:479-491.
5. Curran S, Murray GI. Matrix metalloproteinases in tumor invasion and metastasis[J].Pathol, 1999, 189(3):300-308.
6. Takabashi C, Sheng Z. Horan TP et al. Regulation of matrix metalloproteinase-9 and inhibition of tumor invasion by the membrahe-anchored glycoprotein RECK[J]. Proe Nail Acad Sci USA, 1998, 95(22): 13221-13226.
7. Clark JC, Thomas DM, Choong PF,et al.RECK-a newly discovered inhibitor of metastasis with prognostic significance in multiple forms of cancer[J] .Cancer Metastasis Rev. 2007,26(3-4):675-683.
8. Oh, J. The membrane-anchored MMP inhibitor RECK is a key regulator of extracellular matrix integrity and angiogenesis[J]. Cell, 2001, 107(6):789-800.
9. Rhee JS, Coussens LM. RECKing MMP function: implications for cancer development[J]. Trends in Cell Biology, 2002,12 (5):209-211.
10. Takagi S, Simizu S, Osada H. RECK negatively regulates matrix metalloproteinase-9 transcription. Cancer Res. 2009 ,69(4):1502-1508.
11. Omura A, Matsuzaki T, Mio K, et al.RECK forms cowbell-shaped dimers and inhibits matrix metalloproteinase-catalyzed cleavage of fibronectin. J Biol Chem.2009,284(6):3461-3469.
12. Welm B, Mott J, Werb Z. Developmental biology: vasculogenesis is a wreck without RECK[J].Curr Biol, 2002,12(6): 209-211.
13. Brew K, Dinakarpandian D, Nagase H. Tissue inhibitors of metalloproteiNases:evolution, structure and function[J]. Biochim Biophys Acta, 2000,1477(12): 267-283.
14. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis[J]. Cell, 1996, 86(3):353-364.
15. Stetler-Stevenson WG. Matrix metalloproteinases in angiogenesis:a moving target for therapeutic intervention[J]. J Clin Invest, 1999,103(9):1237-1241.
16. Kim SK,Ro JY,Kemp BL,et al.Identification of three distinct tumor suppressor loci on the short arm of chromosome 9 in small eel lung cancer[J].Cancer Res, 1997,57(2): 400-403.
17. Yoshida D, Nomura R, Teramoto A.Regulation of cell invasion and signalling pathways in the pituitary adenoma cell line, HP-75, by reversion-inducing cysteine-rich protein with kazal motifs (RECK). J Neurooncol. 2008,89(2): 141-150.
18. Li SL, Gao DL, Zhao ZH,et al.Correlation of matrix metalloproteinase suppressor genes RECK, VEGF, and CD105 with angiogenesis and biological behavior in esophageal squamous cell carcinoma[J].World J Gastroenterol. 2007,13(45):6076-6081.
19. Takemoto N, Tada M, Hida Y,et al. Low expression of reversion-inducing cysteine-rich protein with Kazal motifs (RECK) indicates a shorter survival after resection in patients with adenocarcinoma of the lung.Lung Cancer[J].2007,58(3):376-383.
20. Chang CK, Hung WC, Chang HC.The Kazal motifs of RECK protein inhibit MMP-9 secretion and activity and reduce metastasis of lung cancer cells in vitro and in vivo[J].J Cell Mol Med.2008, 12(6B):2781-2789.
21. Long NK, Kato K, Yamashita T,et al.Hypermethylation of the RECK gene predicts poor prognosis in oral squamous cell carcinomas. Oral Oncol. 2008 May 14. [Epub ahead of print].
22. Kang HG, Kim HS, Kim KJ, et al. RECK expression in osteosarcoma:correlation with matrix metalloproteinases activation and tumor invasiness[J]. J Orthop Res, 2007,25(5): 696-702.
23. van Lent PL, Span PN, Sloetjes AW, et al. Expression and localisation of the new metalloproteinase inhibitor RECK (reversion inducing cysteine-rich protein with Kazal motifs) in inflamed synovial membranes of patients with rheumatoid arthritis [J].Annals of the Rheumatic Diseases, 2005,64(3): 368-374.
24. Takeuchi T, Hisanaga M, Nagao M, et al. The membrane-anchored matrix metalloproteinase (MMP) regulator RECK in combination with MMP-9 serves as an informative prognostic indicator for colorectal cancer[J]. Clinical Cancer Research,2004,10(16): 5572-5579.
25. Liu LT, Chang HC, Chiang LC, et al. Histone deacetylase inhibitor up-regulates RECK to inhibit MMP-2 activation and cancer cell invasion[J]. Cancer Res,2003 ;63:.3069-3072
